By Daniella Parra
ProSomnus, Inc. (NASDAQ: OSA) said it plans to conduct a clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation for severe obstructive sleep apnea treatment.
This follows positive preliminary data from a study that demonstrated the effectiveness of its approach as a first-line therapy for moderate to severe obstructive sleep apnea, the company said.
Separately, ProSomnus shared data showing that precision devices had higher success rates and lower adverse events and treatment costs compared to nerve stimulation.
Contact:
Editor@Executives-edge.com
